GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (OTCPK:DCHPF) » Definitions » Cash Conversion Cycle

Dechra Pharmaceuticals (Dechra Pharmaceuticals) Cash Conversion Cycle : 197.06 (As of Jun. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Dechra Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Dechra Pharmaceuticals's Days Sales Outstanding for the six months ended in Jun. 2023 was 63.11.
Dechra Pharmaceuticals's Days Inventory for the six months ended in Jun. 2023 was 227.18.
Dechra Pharmaceuticals's Days Payable for the six months ended in Jun. 2023 was 93.23.
Therefore, Dechra Pharmaceuticals's Cash Conversion Cycle (CCC) for the six months ended in Jun. 2023 was 197.06.


Dechra Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for Dechra Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Cash Conversion Cycle Chart

Dechra Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 176.50 190.41 180.89 219.25 226.65

Dechra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 148.68 157.03 165.05 182.36 197.06

Competitive Comparison of Dechra Pharmaceuticals's Cash Conversion Cycle

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dechra Pharmaceuticals's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's Cash Conversion Cycle falls into.



Dechra Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Dechra Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Jun. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=63.1+211.61-48.06
=226.65

Dechra Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Jun. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=63.11+227.18-93.23
=197.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dechra Pharmaceuticals  (OTCPK:DCHPF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Dechra Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Dechra Pharmaceuticals (Dechra Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (Dechra Pharmaceuticals) Headlines

From GuruFocus

Ron Baron Comments on Dechra Pharmaceuticals PLC

By Holly LaFon Holly LaFon 01-24-2019

Ron Baron Comments on Dechra Pharmaceuticals

By Sydnee Gatewood Sydnee Gatewood 07-29-2020